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Abstract: Individuals with diabetic kidney disease are at high risk of complications and challenged to
self-manage. Previous research suggested that multidisciplinary approaches would improve health
outcomes. This study investigated the effect of a multidisciplinary self-management approach of
diabetic kidney disease on quality of life, and self-management, glycemic control, and renal function.
A uniform balanced crossover design was used because it attains a high level of statistical power
with a lower sample size. A total of 32 participants (aged 67.8 ± 10.8) were randomized into four
study arms. In differing sequences, each participant was treated twice with three months of usual
care alternated with three months of multidisciplinary management. The intervention improved
the present dimension of quality of life demonstrating higher mean rank as compared to usual care
(52.49 vs. 41.01; p = 0.026, 95% CI) and three self-care activities, general diet habits, diabetes diet
habits, and blood sugar testing (respectively: 55.43 vs. 38.31; p = 0.002, 56.84 vs. 37.02; p = 0.000,
53.84 vs. 39.77; p = 0.008; 95% CI). Antihypertensive medication engagement was high across the
study period (Mean = 95.38%, Min = 69%, Max = 100%). Glycemic control and renal function
indicators were similar for the intervention and the usual care. Studies are needed to determine how
the new recommended therapies for diabetic kidney disease such as SGLT2 inhibitors and GLP-1
receptor agonists impact on self-management and quality of life.
Keywords: self-management support; self-management interventions; multidisciplinary care;
interdisciplinary studies; diabetic nephropathy; randomized crossover
1. Introduction
Worldwide healthcare systems are facing the challenges of the high prevalence [1] and the
progressive increase [2] of Diabetic Kidney Disease (DKD).
DKD is a micro-vascular complication of diabetes that induces a progressive decline in renal
function, over five stages, leading to kidney failure [3]. It remains the leading cause of end-stage kidney
disease [4] and highly increases the risk of cardiovascular complications [5]. DKD treatment aims
at slowing the progression of the kidney disease, preventing cardiovascular events, and improving
Quality of Life (QoL) [3,6], especially since the QoL of people with DKD was shown to decrease
progressively in parallel to kidney function decline [7]. Individuals with DKD are challenged by the
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complexity of the expected daily self-management related to diabetes and other comorbidities like
hypertension [6,8,9]. These self-care activities include blood glucose monitoring, nutrition adjustment,
physical activity, medication engagement, detection and symptoms management, complications risk
reduction, and psychosocial adjustment to treatment [10].
The multidisciplinary management of DKD is one way to help individuals overcome
self-management challenges, achieve treatment goals, and improve health outcomes [11], especially
when consolidated by health education tailored to comorbidities, and addressing fear and coping
mechanisms [12].
A meta-analysis of multidisciplinary management of DKD included three randomized
controlled trials, and demonstrated a significant improvement in glycated hemoglobin (HbA1c)
in multidisciplinary management as compared to standard Usual Care (UC). The results did not show
a difference related to other clinical outcomes. Only one included study measured person-reported
outcomes and demonstrated an improvement in QoL, self-care activities, and level of knowledge on
diabetes. These studies were not based on a nursing theory, and did not include a nursing central role
or an individualization of care based on participants’ needs with personalized goal setting [13].
In one qualitative study, participants with chronic kidney disease (CKD) expressed needs of
guidance and support for achieving self-management [14]. Another study highlighted the importance
of considering individuals’ illness perception along with stressors, and expectations related to the
disease, oneself, social interactions, and dependency on others [15]. Individuals with CKD seem to
have a diverse understanding of the disease and its trajectory but voice a need for information and
psychosocial support [16]. Nurses are best fit to answer these expressed needs.
Multidisciplinary self-management support for DKD, which is based on a nursing theory,
is understudied. Nurses’ role in multidisciplinary care was described in five main interventions:
(1) helping individuals in developing self-care abilities, (2) guiding individuals in symptom monitoring,
problem-solving techniques, and establishment of priority health goals, (3) providing a follow-up in
different settings and using reminders, (4) monitoring progress towards set goals, and (5) coordinating
care. The interventions focused on self-management development for achieving treatment targets.
Therefore, the Self-Care Deficit Nursing Theory (SCDNT) was adopted to guide this study and the
nursing practice within the multidisciplinary program. The SCDNT stipulates that actual, or potential,
deficits are established when individuals are unable to meet their self-care demands. Nursing, a helping
and health regulatory system, intervenes to support individuals in overcoming these self-care deficits.
The nurse delivers deliberate care in coordination with the individual who carries own self-care [17].
A nursing theory-based approach applied to the multidisciplinary management of DKD, in ambulatory
services, could improve health outcomes.
The primary aim of this study was to determine the effect of a Multidisciplinary Self- Management
Support Program (MSMP) on QoL of adults with DKD as compared to UC. The secondary aim was to
determine the effect of the MSMP on self-care activities, glycemic control, and renal function of adults
with DKD as compared to UC.
2. Materials and Methods
2.1. Study Design
A uniform and strongly balanced crossover design was used to determine the effectiveness
of MSMP as compared to UC in individuals with DKD. This crossover design represents the ideal
crossover that is able to overcome the statistical bias of the carry-over effect [18]. This design is uniform
within sequences and within periods: each treatment appears the same number of times within each
sequence, and the same number of times within each period. It is balanced with respect to carryover
effects, because each treatment precedes every other treatment, including itself, the same number
of times.
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DKD represents approximately 25–30% of the population with diabetes, limiting the possibility
for large sample recruitment. This crossover design is recommended for an efficient comparison of
treatments when recruiting a small group of participants in order to attain the same level of statistical
power, or precision as a randomized controlled trial. It requires a sample size that is 14 of the randomized
controlled trial sample size, because the within-patient variances are one-fourth that of the inter-patient
variances [18].
This can be used for comparing treatments of chronic conditions when the treatment aims at
improving quality of life and preventing complications. In crossover design, each participant receives
the treatment and serve as his or her own control, thus limiting the mixed effects of the heterogeneity
in populations with different comorbidities. The focus of a uniform balanced crossover design is
to compare the participants’ responses to two different treatments. This design does not allow for
a comparison of the participants within differences in the values of variables over time [18].
UC was considered as one of the treatment options of this crossover, therefore, a washout period
was not included in the study. Introducing a washout period would have deprived participants
of UC, and prevented any contact between participants and their nephrologists, or diabetologists.
Given the chronicity of DKD, keeping participants from standard treatment would have been unethical.
Our decision is in line with a recent publication on the crossover design [19].
The study was carried out at the ambulatory services of a university hospital and in private
practice. Participants were enrolled in the study for 12 months and were allocated to one of the four
sequences of the crossover. They received the UC twice, each time over three months, alternating
with twice the MSMP, also each time over three months, in a specific sequence depending on their
allocation. All participants crossed over from period 1 to 2, then to 3, and finally to 4 (Table 1 black
arrow). With each crossover, the UC or MSMP set of interventions was restarted.
Table 1. Crossover plan of participants enrolled in the study.
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2.2. Study Participants
Nephrologists of the Lausanne university hospital, and diabetologists in private practice recruited
participants who were 18 years or older, with a clinical diagnosis of diabetes, and kidney disease,
with no cognitive deficit, not on dialysis or with a terminal illness. Kidney disease was confirmed by
an estimated glomerular filtration rate (eGFR) <60 mL/min calculated using the CKD Epidemiology
Collaboration (CKD_EPI) formula, or an Albumin/Creatinine ratio (Alb/Cr) ≥30 mg/mmol.
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All participants signed an informed consent and were free to withdraw from the study at any
time, with no prejudice to their care.
2.3. Randomization and Masking
Physicians (nephrologists and diabetologists) recruited the participants and were not involved
in randomization. A departmental research nurse, who was not involved in the study, allocated the
participants to one of the four study sequences using a computerized random number generator.
To ensure assessor blinding, an independent private laboratory blinded to the study protocol and
participants’ allocation, carried the analyses of the blood and urine sample, and entered the study
clinical data. A computer assistant blinded to treatment allocation was responsible for overseeing the
data entry of the self-administered questionnaires. Medication monitoring was recorded daily by the
Medication Events Monitoring System (MEMS) over 12 months. An independent statistician blinded
to the allocation sequences carried out data analysis. Pre-to-post-test outcome comparisons were done
by treatment condition, regardless of the sequence of treatment received, to overcome any influence of
unmasking of the intervention to participants (Table 1 grey arrows).
2.4. Intervention
The study team and the university hospital nephrologists discussed, amended and approved the
intervention, and its documentation materials were pilot tested on two volunteers before the start of
the study.
The UC consisted of a follow-up by the general practitioner, nephrologist, and/or diabetologist,
including a visit to the nephrologist and the diabetologist once every 3 months.
The MSMP consisted of the same follow-up by the general practitioner, nephrologist and/or
diabetologist, but added care was provided by an Advanced Practice Nurse (APN), a nurse specialized
in diabetes care and a clinical dietician. The APN ensured referrals to physiotherapists, pharmacists,
social workers and other healthcare professionals, when needed.
The MSMP alternated nursing and dietary care with the usual nephrology and diabetology
consultations to ensure a direct or telephone contact every two weeks with a healthcare professional.
In each MSMP period, participants received two dietary consultations, three nursing consultations at
their home or at the ambulatory clinic, and two nursing telephone follow-ups. The description of one
of the MSMP sequence is shown in Table 2. Each nursing and dietary consultation lasted for one hour,
except the first nursing consultations of each MSMP, which lasted one and a half hours.
The APN was responsible for ensuring evidenced-based nursing, managing the MSMP,
and coordinating care between healthcare professionals.
The nursing intervention was structured and based on the SCDNT theory. It was built using
specific nursing assessment, follow-up documentations, and educational materials that were adapted
to the purpose of the study.
The diabetes specialized nurse conducted a comprehensive initial clinical and psychosocial
assessment of the participant, and an evaluation of medication safety. She assisted the participant
in setting a priority treatment goal and signing a self-management contract for achieving the goal.
She developed a collaborative care plan and delivered nursing interventions to help the participant to
meet the set goal. She guided participants in symptom monitoring, and problem-solving techniques.
She helped participants develop their self-care abilities, identifying and using their resources, engaging
in medication taking, and following an exercise regimen (walking at least 90 min per week) and dietary
recommendations. She monitored participants’ progress towards achieving set goals. She provided
psychosocial support and teaching on diabetes and kidney protection.
The dietician adopted a self-management approach and set an individualized dietary plan.
To ensure fidelity to the intervention, the APN monitored the scheduled appointments and the
self-management contract between the diabetes nurse and the participants, describing the set objectives
and the plan of care, along with the follow-up documentations.
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2.5. Outcome Measures
Data were collected at baseline, and after each follow-up period of 3 months, for all outcome
measurements between 1 April 2014 and 20 January 2016.
QoL, the primary outcome of the study, was assessed using the Audit of Diabetes-Dependent
QoL (ADDQoL) measure, a self-administered questionnaire of 19 items with a weighted score ranging
from −9 to 9. It covers three separate dimensions of QoL: Present QoL, Impact of diabetes on QoL,
and Impact of diabetes on life domains including social life, physical health, self-confidence, motivation,
feelings about the future, dependency on others, and living conditions (α = 0.947) [20].
Self-care activities were evaluated using the self-reported questionnaire Revised Summary of
Diabetes Self-Care Activities (R-SDSCA), and electronic monitoring of anti-hypertensive medication
taking. The R-SDSCA is a self-administered questionnaire of 10 items covering independent activity
domains namely dietary habits, physical activity, blood glucose monitoring, foot care, and smoking
(mean r = 0.47; except for diet r = 0.40) [21].
The engagement in anti-hypertensive medication taking was measured using electronic monitoring
MEMS [22]. Medication monitoring was recorded daily by the MEMS over 12 months. An average
three-month engagement percent was computed for every UC and MSMP period.
Glycemic control was evaluated through HbA1c measurement and renal function through the
measurement of serum creatinine, urinary Alb/Cr and eGFR using CKD_EPI formula.
The number of times that participants used help from the MSMP team, outside the defined
frequency, was calculated.
2.6. Statistical Analysis and Data Management
Targeted ample size was calculated based on the primary outcome QoL. Considering the crossover
design, 40 participants were required to detect a 20% clinically significant absolute difference [23] on
the ADDQoL for diabetes complications [24], at an α of 0.05, and a power of 0.08, accounting for a 20%
expected drop-out rate.
The data were analyzed using SPSS for Windows version 22. p-values < 0.05 were considered
statistically significant.
Crossover designs have a paired nature, with each participant serving as their own control.
Therefore, we reported results using within-individual-treatment differences accounting for point
estimates (mean differences), and precision estimate (SD, min and max), based on reporting
recommendations for the results of crossover designs [19]. Differences in variables were calculated
from timepoints to baseline, for each sequence, to prohibit extreme values from playing a pivotal role
in statistical analysis. This pre-to-post-test outcome comparison was done by treatment condition,
regardless of the sequence of treatment received (Table 1 grey arrows). The analysis followed the
intent-to-treat principle.
The study was registered at ClinicalTrials.gov NCT01967901, on 18 March 2013.
The deidentified participants’ datasets used and analyzed during this study are available from
the corresponding author on reasonable request, with a signed data access agreement.
The majority of our dependent variables were not normally distributed. Consequently,
the Mann–Whitney-U test, a non-specific statistical test, was used to look for significant overall
differences between the intervention and the control, on the dependent variables, comparing mean
ranks rather than medians.
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Table 2. The schedule, description, and outcome measurement of the multidisciplinary self-management program (MSMP) sequence-BAAB for patients with diabetic
kidney disease (DKD).
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3. Results
A total of 84 individuals were found to be eligible for recruitment. A total of 32 (mean age
67.8 ± 10.8; 90.6% men) agreed to participate between 1 April 2014 and 20 January 2015. Participants had,
on average, 3.5 comorbidities (Table 3).
Table 3. Characteristics of Study Participants (n = 32).
Clinical Characteristics Range Mean (±SD)/Median
Age (years) 50–91 67.8 (±10.8)/67
HbA1c (%) 5.7–10.5 7.7 (±1.3)/7.45
eGFR (mL/min/ 1.73 m2) 15–108 41.3 (±21.5)/35
Sociodemographic Characteristics Frequency %
Age Group 50–64 14 43.8
65–80 13 40.6
≥80 5 15.6
Sex Men 29 90.6
Women 3 9.4
Marital Status Married/ Cohabitating 21 65.6
Divorced/Living alone 11 34.4
Professional Status Retired 18 56.3
Independent/Employed 10 31.2
Medical cessation of work 4 12.5
Educational Level Academic 11 34.4
Short-cycle/Post-secondary 12 37.5
Primary 9 28.1





Peripheral vascular disease 8 25
Gout 3 9
Sleep apnea 7 22
Medications Insulin 22 69
ACE inhibitor or ARB 27 84
GLP-1Ra 2 6
SGLT2i 0 0
Five participants withdrew from the study. These withdrawals occurred in the two sequences
which did not start with the MSMP directly at enrollment. One participant with stage 4 DKD
was excluded from the study because his renal function declined, and he started hemodialysis.
Two participants passed away during the study (Figure 1).
MSMP was found to improve the general QoL of individuals with DKD as compared to UC,
with a highest significant mean rank (52.49 vs. 41.01; p = 0.026, 95% confidence interval), considering
a 20% improvement as a clinically significant absolute difference [23] (Table 4). However, the UC and
the MSMP showed no difference in relation to the impact of diabetes on QoL and on life domains.
Three self-care activities, which were at the heart of our intervention, demonstrated significant
differences between MSMP and UC. General diet habits, diabetes diet habits and blood sugar testing
all showed significant improvement for MSMP as compared to UC (respective ranks 55.43 vs. 38.31;
p = 0.002, 56.84 vs. 37.02; p = 0.000, and 53.84 vs. 39.77; p = 0.008; 95% confidence interval).
The antihypertensive medication monitoring results did not differ between MSMP and UC
(Table 4). However, the medication monitoring overall percentage mean was high across UC and
MSMP, for all participants who used it, over 12 months of the study duration (n = 21, Mean = 95.38%,
SD = 7.29, Min = 69%, Max = 100%).
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The results did not demonstrate significant differences between MSMP and UC in the clinical
indicators related to glycemic control and renal function (Table 4). Absolute values are presented in
Supplementary Materials Tables S1–S12.
All participants who completed the study received, in each MSMP period, the full number of
consultations as per protocol. Eleven participants needed supplementary consultations, which mainly
consisted of nursing telephone calls.J. Clin. Med. 2020, 9, x FOR PEER REVIEW  9 of 15 
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Table 4. Changes in quality of life (QoL), Self-Management, Glycemic Control, and Renal Function between MSMP and usual care (UC).
Variable Measure
Pre-Post Difference
n Mean Rank Rank Sum Mean SD n Mean Rank Rank Sum Mean SD M-U Sig.
UC MSMP
Quality of Life ADDQoL
Present QoL 48 41.01 1968.5 −0.19 0.87 44 52.49 2309.5 0.18 1.06 792.5 0.026 *
DM Impact on QoL 48 47.24 2267.5 0.06 1.19 44 45.69 2010.5 −0.05 0.96 1021 0.763
DM Impact on Domains 48 43.03 2065.5 −0.11 0.95 44 50.28 2212.5 −0.06 1.44 889.5 0.193
Self-Management R-SDSCA
General Diet Habits 48 38.31 1839 −0.46 1.94 44 55.43 2439 0.93 1.66 663.0 0.002 *
DM Specific Diet Habits 48 37.02 1777 −0.19 1.06 44 56.84 2501 0.82 1.85 601.0 0.000 *
Exercise Habits 48 45.21 2170 0.30 2.66 44 47.91 2108 0.47 2.38 994.0 0.626
Blood Sugar Testing 48 39.77 1909 −0.58 2.54 44 53.84 2369 0.80 2.22 733.0 0.008 *
Foot Care 48 43.34 2080.5 −0.14 1.88 44 49.94 2197.5 0.25 1.65 904.5 0.214
% of Smoking Status 48 47.90 2299 0.04 0.20 44 44.98 1979 −0.02 0.15 989.0 0.089
No· of cigarettes/ day 9 10.22 92 −0.44 4.10 9 8.78 79 −1.22 6.22 34.00 0.558
MEMS Anti-HTN Medication 26 21.79 566.5 −3.08 12.1 22 27.71 609.5 −1.32 6.44 215.5 0.140
Glycemic Control % HbA1c 56 56.51 3164.5 0.06 0.64 50 50.13 2506.5 −0.17 0.87 1232 0.285
Renal Function
µmol/L Serum Creatinine 55 52.62 2894 −3.44 32.3 51 54.45 2777 1.47 28.8 1354 0.759
mL/min eGFR (CKD_EPI) 57 57.75 3291.5 1.51 12.4 51 50.87 2594.5 −0.20 9.48 1269 0.254
mg/mmol Urine Alb/Cr 46 49.35 2270 9.89 103 46 43.65 2008 −2.60 103 927.0 0.306
Anti-HTN= Antihypertensive; DM = Diabetes Mellitus; Exercise Habits = frequency of physical activity /week; M-U = Mann–Whitney U; * Significant p-values; Intent to treat data
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4. Discussion
Participants were predominantly men with an age range of 50–91 years (Table 3); thus, our
results can mainly be generalized to men. Studies on the multidisciplinary management of DKD
were conducted in different sociocultural environments. They reported diverse sex percentage and
an age range of 44–74.6% [25–29]. One report showed >50% higher diabetes prevalence in men [30,31].
Age and sex differences in DKD might be affected by diabetes prevalence, genetic predispositions,
sociocultural, and environmental factors. Our intervention was based on the SCDNT, which aims to
improve QoL by helping people to gain knowledge on self-management [17]. The results showed
a significant increase in general QoL and three of their self-care activities, which is in line with a previous
study results [29]. This new approach generated an additional cost of 1200 per patient, extrapolating
an annual additional cost of 16–17 million to cover the national DKD population.
The findings are consistent with the SCDNT theoretical assumptions and basis. The nursing
theory-based intervention did contribute to the short-term outcomes, namely self-care activities,
which are central to the theory and expected to mediate long-term outcomes like the stability of the
kidney function. The MSMP was built, as a whole, to promote participants’ capabilities in carrying out
their own self-management. Puzzling out the contribution of each self-management activity to the
clinical results is not possible at this time.
To our knowledge, our study is the first to measure medication engagement and use of MEMS
in DKD. The results revealed a high engagement (over 12 months). In the literature, the electronic
monitoring of medication in diabetes was variable, ranging from 53 to 98% [32]. We blinded participants
to the daily reading of the MEMS, which was used as a self-dispensing medication container over
a long period of 12 months. Consequently, the higher percentage of engagement cannot be related to
the use of electronic monitoring.
Mean HbA1c at baseline was 7.7%, which represented a reasonable clinical goal given the higher
risk of hypoglycemia in DKD; therefore, and despite a significant increase in blood glucose testing,
the results could not demonstrate a further improvement in glycemic control with the multidisciplinary
management, in contrast to the meta-analysis that pooled the data of three studies [13]. Two of the
studies included in the meta-analysis found no effect of multidisciplinary management on HbA1c
at three [29] and 12 months [27], while the third study demonstrated significantly lower HbA1c at
24 months [25].
The present study mean baseline eGFR represented moderate kidney damage (stage 3) congruent
with similar studies [25–29]. The results were similar to those of the meta-analysis that could not find
evidence supporting multidisciplinary management in delaying the progression of DKD [13], despite
the high antihypertensive medication engagement. The actual slowing of the renal function decline
rate may become evident after 24 months [33]. Nevertheless, addressing current clinical status [34]
and focusing on QoL and daily self-management is central to individuals with DKD. Thus, they would
be supported in coping with uncertainty. As a result, their physical and emotional wellbeing would be
improved. Only two participants were on GLP-1 receptor agonists and none were on SGLT2 inhibitors
because these medications had only just arrived on the Swiss market at the beginning of the study.
SGLT2 inhibitors have been shown to reduce the risk of renal disease progression in diabetes [35].
The use of these two medications has recently been recommended [36] and their new combination
therapy could be promising for improving blood pressure, glycemic control, renal function [37,38] and
QoL [39].
A major limitation of the study can be attributed to the non-attainment of the anticipated
recruitment of 40 participants. Recruitment was extended for an additional six-month period and was
expanded to diabetologists, and nephrologists of the private sector near the participating hospital.
However, more than half of the eligible participants were already involved in other studies.
Two study sequences, starting with UC at enrollment, witnessed participants’ withdrawal.
Dropouts did not occur in the two sequences that started with MSMP at enrollment. The retention of
participants in the study could have been improved if participants starting with UC were reminded
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regularly of the study plan. One can assume that, with time, participants were facing the burden of the
advancing disease and were less able to invest in research.
With the recent evidence that SGLT2 inhibitors and GLP1-R agonists provide cardio-renal
protection in high-risk individuals with type 2 diabetes, their use should now be considered as
a standard of care. Studies are required to determine the effect of GLP-1 receptor agonists’ and SGLT2
inhibitors’ use in multidisciplinary self-management support of DKD and QoL. Further research is
needed to compare multidisciplinary self-management support to other self-management approaches
like the Stanford approach, which relies on peer support [40], or other care delivery modalities like
web-based interventions and applications.
5. Conclusions
This study was unique in integrating a nursing theory-based intervention within a multidisciplinary
management approach. MSMP was a complex intervention aiming to promote self-management.
The general QoL and self-management activities of individuals with DKD were improved. The MSMP
supported the importance of nursing theory-guided practice and the significant role of specialized
nurses as part of multidisciplinary teams. It highlighted the advanced role for nurses in promoting
chronic disease self-management. However, multidisciplinary approaches and self-management
support should start before or at the early stages of renal disease or albuminuria. A combination
of new therapies, namely SGLT2 inhibitors and GLP-1 receptor agonists, may positively contribute
to individuals’ self-management abilities and glycemic control, leading to an improvement in renal
outcomes, DKD experience and thus QoL. Research should also address the direct effect of the
combination of these new therapies on QoL, in individuals with established or advanced DKD.
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